Chordate Medical

Chordate Medical occupies a specialized position within medical devices and therapeutic neuromodulation. Its core offering, OZILIA®, is a drug-free, CE-marked treatment for chronic migraine and rhinitis-related nasal congestion. The company differentiates itself through Kinetic Oscillation Stimulation delivered via nasal application to target the sphenopalatine ganglion, rather than competing solely through pharmaceuticals or conventional implantable neuromodulation. Its focus on both migraine and nasal congestion gives it a broader clinical-use case than a single-indication device, while the company’s stated clinical evidence and patent portfolio support differentiation in a crowded headache-treatment market. Chordate is a public company listed under STO:CMH, but its disclosed employee range is only one to ten people, indicating a substantially smaller operating footprint than established pharmaceutical and device competitors. Its selected-market rollout in Europe and the Middle East suggests an international commercialization model, though adoption, revenue scale, and payer coverage remain unclear.

Chordate Medical’s trajectory reflects a long product-development cycle followed by focused commercialization and financing activity. Founded in 2005, the company spent approximately a decade developing and patenting OZILIA® before presenting it as a CE-marked treatment for chronic migraine and rhinitis. It became publicly listed on Mar 8, 2017, creating access to post-IPO financing while retaining a very small disclosed workforce of one to ten employees. The clearest recent inflection point was the Nov 20, 2024 exercise of warrants, which generated approximately $279,041 in recorded proceeds. A further rights issue announced for February 2025 was described at SEK 17.7 million, although the amount does not reconcile with the structured financing total. Clinical visibility improved on Jan 14, 2025 when study results were published in Neurology, followed by US Ozilia trademark registration announcements on Apr 10, 2025 and Apr 15, 2025. The company has also introduced treatment in selected European and Middle Eastern markets. Overall, growth appears milestone-driven and capital-constrained, with evidence, branding, and market access advancing ahead of demonstrable scale.